Quick Answer
C4 Therapeutics, Inc. reported Stockholders Equity of $256.59 million for fiscal year 2025.
C4 Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $256.59M | +18.8% |
| 2024 | $215.99M | -12.2% |
| 2023 | $246.11M | -14.9% |
| 2022 | $289.23M | -25.8% |
| 2021 | $389.61M | +38.8% |
| 2020 | $280.79M | +350.8% |
| 2019 | -$111.96M | -40.4% |
| 2018 | -$79.75M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $154.41M | -36.4% | -11.3% |
| June 30, 2025 | $174.06M | -29.5% | -10.8% |
| March 31, 2025 | $195.14M | -24.4% | -9.7% |
| December 31, 2024 | $215.99M | -12.2% | -11.0% |
| September 30, 2024 | $242.66M | +12.3% | -1.8% |
| June 30, 2024 | $247.06M | +5.7% | -4.3% |
| March 31, 2024 | $258.28M | -1.6% | +4.9% |
| December 31, 2023 | $246.11M | -14.9% | +13.9% |
- C4 Therapeutics, Inc. showed an increase of +18.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, C4 Therapeutics, Inc.’s stockholders equity has grown by 421.7% (from -$79.75 million to $256.59 million).
- The most recent figure is from C4 Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: